Find Academic Supervisors

• Pulmonary vasculature
• Heart Failure
• Cardiopulmonary Immunology

Michael Yeager, PhD, serves as an Associate Clinical Professor in the School of Medicine at the University of Colorado Denver, focusing on cardiopulmonary pathophysiology with emphasis on pulmonary hypertension and heart failure mechanisms. He completed his PhD at the University of Colorado Health Sciences Center in 2002, establishing foundational expertise in vascular biology. His research program investigates immunological and molecular drivers of pulmonary vascular disease, particularly the roles of autoantibodies, fibrocytes, and inflammatory cascades in disease progression. Analysis of his 14 publications (2012-2015) reveals consistent exploration of biomarker discovery, vascular remodeling, and immune dysregulation across pediatric and adult pulmonary hypertension. Key methodological approaches include proteomics, animal modeling, and molecular interrogation of cellular stress responses, with significant translational implications for personalized therapeutic strategies. Professional recognitions include: Outstanding Faculty award from Tau Beta Pi (2019) Chancellor's Teaching Recognition Award from the University of Colorado (2016) Dr. Yeager maintains active clinical research collaborations at Children's Hospital Colorado while mentoring within the medical school curriculum. His work bridges basic science discovery with clinical application through ongoing investigations into endothelial dysfunction and inflammatory mediators. Affiliated with the Department of Medicine, he contributes to pulmonary vascular research initiatives and participates in professional societies including the American Thoracic Society, American Heart Association, and T21 Research Society.

Ilse DewachterView profile

Professor

• Alzheimer's Disease
• Neurodegenerative Diseases
• Therapeutic Development
• +6 more

Prof. Ilse Dewachter is the head of the Biomed Neuroscience research group at Hasselt University (UHasselt), specializing in Alzheimer’s therapy and prevention for over 25 years. Her work focuses on multi-targeted therapies targeting tau, inflammation, and ApoE, alongside pioneering research into disease prevention via blood-based biomarkers. Recent studies explore a protective APOE3ch mutation that halted Alzheimer’s progression in a patient, offering hope for new treatments. Research Interests: - Alzheimer’s disease mechanisms (Abeta, tau, inflammation) - Multi-target therapies and biomarker development - Neurodegenerative disease prevention strategies - Genetic mutations impacting disease progression Articles Overview: Her most recent work (2025-2022) addresses neuroinflammation, tau propagation models, and AI-driven neuroimaging. Key themes include APOE genetics, blood-brain barrier dynamics, and exercise impacts on cognition. Funding & Grants: Current projects require significant investment for advanced biomarker equipment and clinical trials. A notable €300,000 grant funded research on brain lipid metabolism’s role in Alzheimer’s. Labs & Teams: Leads the BIOMED Neuroscience group at UHasselt, collaborating internationally on preclinical models and drug development.

• Neurodegenerative Diseases
• Molecular Neuroscience
• Stem Cell Research
• +3 more

Professor Richard Wade-Martins is a leading academic in University of Oxford 's Department of Physiology, Anatomy and Genetics . He directs the Molecular Neurodegeneration Research Laboratory and the Oxford Parkinson’s Disease Centre (OPDC). With degrees from Cambridge (MA) and Oxford (DPhil), he has held prestigious fellowships including Wellcome Trust Research Career Development Fellowship and NIH reviewer roles. His research targets molecular mechanisms in Parkinson’s and Alzheimer’s diseases through iPSC models , transgenic mice , and lysosomal function studies . He pioneered work on SNCA , MAPT , and LRRK2 gene pathways. Current projects focus on gene therapy and mitochondrial dysfunction in neurodegeneration. Key publications (2019–2025) reveal trends in single-cell transcriptomics , calcium channel inhibition , and TFEB/TFE3 lysosome modulation . His awards include Wellcome Trust Fellowships and advisory roles for Parkinson's UK , Alzheimer's Research UK , and EU consortia like StemBANCC and EFACTS . He leads the UK Dementia Platform iPSC Initiative and serves on international boards in Luxembourg and Canada.

• Neuroscience
• Neurodegenerative Diseases
• Alzheimer's Disease
• +3 more

Hideyuki Takahashi is an Associate Research Scientist in the Department of Neuroscience at Yale University School of Medicine. He holds a PhD from Waseda University (2005) and has established himself as a prominent researcher in neurodegenerative diseases, particularly focusing on lysosomal biology and protein aggregation mechanisms. Dr. Takahashi's research primarily investigates the role of progranulin, TMEM106B, and other molecular players in neurodegenerative conditions including Alzheimer's disease, frontotemporal dementia, and tauopathies. His work spans multiple approaches from molecular and cellular neuroscience to animal models of disease. His recent publications demonstrate a strong focus on lysosomal dysfunction in neurodegeneration, with particular attention to how TMEM106B interacts with other proteins to influence disease progression. The research trends show increasing emphasis on therapeutic interventions targeting specific molecular pathways involved in protein aggregation and synaptic loss. ORCID: 0009-0004-4969-977X Dr. Takahashi maintains active collaborations with several leading researchers at Yale, most notably with Stephen Strittmatter (with whom he has 16 common publications), as well as Anita Huttner, Anthony Koleske, and Le Zhang. His research program appears well-integrated within Yale's neuroscience community, contributing significantly to our understanding of neurodegenerative disease mechanisms.

Jason YiView profile

Assistant Professor

• Neuroscience
• Molecular Neuroscience
• Developmental Neuroscience
• +6 more

Dr. Jason Yi is an Assistant Professor of Neuroscience at Washington University School of Medicine (WashU Medicine). His research focuses on understanding the molecular pathways that shape nervous system development and function, with particular emphasis on autism spectrum disorders (ASD). He leads the Yi Lab, which investigates the role of the ubiquitin ligase UBE3A in the brain and its implications for neurodevelopmental disorders. Dr. Yi received his BS in Biochemistry and Molecular Biology from Dickinson College in 2001 and his PhD in Pharmacology from Duke University in 2009. His laboratory is broadly interested in the molecular pathways that shape nervous system development and function, with the ultimate goal of understanding how dysfunction in these pathways contributes to disease. The current focus is on autism spectrum disorders (ASD), using genetic information from human patients to guide in vitro and in vivo experiments employing biochemical, genetic manipulation, cell biological, and microscopy techniques. Dr. Yi's research has significant clinical implications, particularly in understanding how UBE3A dysfunction relates to both Angelman syndrome (caused by lack of UBE3A activity) and autism (caused by excessive UBE3A activity). His lab discovered that a single phosphorylation event in UBE3A turns off its ubiquitin ligase activity, and that mutations in this site are linked to autism. This work bridges disease genetics with a mechanistic understanding of ASD neurobiology and aims to define developmental timepoints for ASD onset. Dr. Yi's research has been recognized with numerous prestigious awards: Ruth K. Broad Biomedical Research Foundation Predoctoral Fellowship (2006) F32 Kirschstein National Research Service Award (2011) Christina Castellana Postdoctoral Fellowship (2011-2014) The University of North Carolina Postdoctoral Award for Research Excellence (2015) Bridge to Independence Award, The Simons Foundation (2017) NARSAD Young Investigator Award, Brain and Behavior Research Foundation (2018) Whitehall Foundation Research Grant (2018) Alfred P. Sloan Foundation Research Fellowship (2019) Dr. Yi's research program is supported by significant grant funding from organizations including The Simons Foundation, Brain and Behavior Research Foundation, and the Whitehall Foundation. His work bridges basic molecular neuroscience with clinical implications for neurodevelopmental disorders, particularly autism spectrum disorders. Through his research, Dr. Yi is contributing to a deeper understanding of the molecular mechanisms underlying ASD, which may ultimately lead to new therapeutic approaches and interventions. The Yi Lab maintains a collaborative research environment focused on cutting-edge neuroscience techniques. The lab combines molecular, cellular, and genetic approaches to study UBE3A function and its role in neurodevelopment. Their work utilizes patient-derived genetic information to guide experimental approaches, ensuring clinical relevance to autism spectrum disorders. Dr. Yi is also actively involved in mentoring graduate students and postdoctoral fellows, contributing to the training of the next generation of neuroscientists.

Nika DanialView profile

Associate Professor

• Metabolic Biology
• Cancer Research
• Diabetes
• +4 more

Dr. Nika Danial is an Associate Professor of Cell Biology at Harvard Medical School and the Department of Cancer Biology at Dana-Farber Cancer Institute. She leads the Danial Lab, investigating metabolic mechanisms that regulate cellular adaptation to stress, with a focus on fuel utilization in health and disease. Dr. Danial holds additional roles as Co-Director of the NCI-funded T32 Training Program in Cancer Chemical Biology and Metabolism. Her research integrates biochemistry, mouse models, and metabolomics to study metabolic contributions to cancer, diabetes, and neurological disorders. Education: PhD from Columbia University (1999), postdoctoral training at Harvard Medical School and Dana-Farber under Dr. Stanley Korsmeyer. Key research areas include mitochondrial dynamics, glucose metabolism pathways, and the interplay between inflammation and metabolic signaling. The lab has pioneered studies on how metabolic flexibility impacts disease progression in pancreatic islets, lymphoma subtypes, and neuronal excitability. Publications highlight discoveries in mitochondrial fatty acid oxidation regulation, urea cycle anti-inflammatory mechanisms, and metabolic signatures in cancer subtypes. Her work has implications for developing therapies targeting metabolic vulnerabilities in diseases like diffuse large B-cell lymphoma and type 1 diabetes. The Danial Lab emphasizes rigorous training for the next generation of scientists through mentorship programs and interdisciplinary collaboration.

Karl Peter GieseView profile

Professor

• Neurobiology of Mental Health
• Alzheimer's Disease
• Synaptic Plasticity
• +6 more

Professor Karl Peter Giese holds the position of Professor of Neurobiology of Mental Health and Co-Head of the Basic & Clinical Neuroscience Department at King's College London's Institute of Psychiatry, Psychology & Neuroscience (IoPPN). His research focuses on memory mechanisms in health and disease, particularly Alzheimer's pathology, synaptic dysfunction, and aging effects. He leads projects funded by Alzheimer's Research UK and other institutions, investigating molecular and cellular bases of memory storage. His work bridges experimental models (e.g., mice) with translational insights for clinical applications. He has over 140 publications, including high-impact studies on CYFIP proteins in dementia and CaMKII in synaptic plasticity. Collaborations include researchers at King's College London and international partners. His lab explores mechanisms linking amyloid-beta, tau, and synaptic proteins to cognitive decline, with recent work applying computational methods to model aging brains. Education: PhD from ETH Zurich (1992), MSc Chemistry from Ruhr-University Bochum (1989). Current grants include Alzheimer's Research UK Network Centres and studies on MNK inhibition for Alzheimer's therapies. Projects span protein synthesis dysregulation, thalamic amyloid pathology, and intellectual disability genetics. His research has been featured in Nature Neuroscience , Brain , and Neuron . He advises on translational neuroscience initiatives and mentors early-career researchers.

Jonathan LittleView profile

Professor

• Exercise Physiology
• Metabolism
• Inflammation
• +3 more

Jonathan Little is a Professor at the University of British Columbia Okanagan , affiliated with the Faculty of Health and Social Development and School of Health and Exercise Sciences . He leads the Exercise Metabolism and Inflammation Laboratory (EMIL) , focusing on the intersection of exercise physiology, nutrition, and metabolic disorders. Hons B. Kin – McMaster University, 2005 M.Sc. – University of Saskatchewan, 2007 Ph.D. – McMaster University, 2010 Postdoctoral Fellowship – UBC, 2010-2012 His research investigates how metabolic disruptions in type 2 diabetes affect cellular inflammation and how exercise/nutritional strategies can mitigate these effects. Key areas include high-intensity interval training (HIIT) , nutritional ketosis , and immunometabolic responses . EMIL combines human clinical trials with cellular/molecular experiments, utilizing advanced tools like flow cytometry and metabolic carts. His recent publications emphasize exercise snacks (short, frequent workouts), ketone supplements , and fasting protocols for managing diabetes and obesity. He has received prestigious awards like the Killam Accelerator Fellowship and CIHR New Investigator Award . Killam Accelerator Research Fellowship (2021-2023) Canadian Society for Exercise Physiology Young Investigator Award (2020) UBC Killam Research Fellowship (2018) Michael Smith Foundation for Health Research Scholar (2018-2023) American College of Sports Medicine New Investigator Award (2016) CIHR New Investigator Salary Award (2015-2020) He supervises graduate students in HMKN 313 – Exercise Metabolism and mentors through the HMKN 499 Research Practicum . His lab (EMIL) collaborates with institutions like the BC Diabetes Research Network and serves as an Associate Editor for Applied Physiology, Nutrition and Metabolism .

Pierre MaechlerView profile

Professor

• Mitochondrial metabolism
• Beta-cell function
• Diabetes research
• +5 more

Pierre Maechler is a Professor at the University of Geneva's Faculty of Medicine in the Department of Cell Physiology and Metabolism. His research focuses on mitochondrial metabolism in pancreatic beta cells and its critical role in diabetes pathogenesis, with particular emphasis on glutamate dehydrogenase function and regulation. His laboratory investigates the molecular mechanisms of insulin secretion and beta-cell failure in Type 2 diabetes. Maechler's research interests span mitochondrial metabolism, energy homeostasis, and the molecular pathways linking nutrient sensing to insulin secretion. His work has established crucial connections between glutamate metabolism, beta-cell function, and diabetes development. He investigates how metabolic stressors like glucotoxicity and lipotoxicity impair beta-cell function through mitochondrial dysfunction. His research has expanded to include the role of glutamate dehydrogenase in multiple organs including brain, liver, and muscle, revealing systemic metabolic implications. Analysis of Maechler's publication record shows a sustained focus on beta-cell metabolism with evolving scope. Early work established fundamental mechanisms of glutamate signaling in insulin secretion, while recent publications demonstrate expansion into multi-organ metabolic regulation. His research has identified novel biomarkers for beta-cell mass, explored therapeutic targets for diabetes, and revealed unexpected roles for glutamate dehydrogenase in diverse physiological processes from muscle regeneration to brain function. The consistent thread through his work is understanding how mitochondrial metabolism governs cellular and systemic energy homeostasis. Professor Maechler has mentored numerous PhD students and postdoctoral fellows who have gone on to publish significant work in diabetes research. His laboratory collaborates extensively with clinical researchers to translate basic findings into potential therapeutic approaches for diabetes. Funding for his work likely comes from Swiss National Science Foundation and other European research agencies, supporting investigations into metabolic diseases. Maechler leads the Mitochondria and Energy Metabolism research group at the University of Geneva. His team employs a multidisciplinary approach combining molecular biology, metabolomics, and physiology to investigate metabolic regulation in health and disease. The laboratory maintains strong connections with clinical diabetes researchers, facilitating translational applications of their findings. Current work focuses on identifying novel therapeutic targets for preserving beta-cell function in diabetes.

• Metabolic Signaling
• Pancreatic Islet Biology
• Signal Transduction Pathways
• +4 more

Dr Amin Ardestani , Senior Lecturer in Metabolic Signaling at the Biomedical Institute for Multimorbidity (BIM), Hull York Medical School (HYMS) , specializes in unraveling molecular mechanisms of pancreatic β-cell failure in diabetes. His research program identifies novel therapeutic targets through signal transduction studies in metabolic disorders. Bachelor's in Biology, Tarbiat Moalem University (2004) Master's in Biochemistry, Institute of Biochemistry and Biophysics (2007) PhD in Biology, University of Bremen (2013) Junior Group Leader at University of Bremen (2014-2023) Research focuses on Hippo and mTOR signaling pathways in β-cell biology, autoimmunity, and regeneration. His work bridges mechanistic biology with drug discovery for diabetes, with significant findings on PHLPP1/2 phosphatases and MST1/2 kinases. Recent publications highlight therapeutic strategies for β-cell protection , including small molecule inhibitors (e.g., MST1/2 inhibitors) and metabolic enzyme modulation (LDHA). Collaborative studies explore SARS-CoV-2 interactions with pancreatic cells and cross-talk between acinar and β-cells in diabetes. 2019 JDRF Advanced Postdoctoral Fellowship 2018 Impulse grant & Career Advancement Award 2017 Early Investigators awards (Endocrine Society, EFSD/Lilly Programme) 2014 Albert Renold Fellowship & Bremer Studienpreis Professional roles include Editorial Board Member at Scientific Reports and Associate Editor at Frontiers in Endocrinology . He reviews grants for DFG, Diabetes UK, and ISF, and evaluates manuscripts for top-tier journals like Cell Metabolism and Nature Communications.

Roderick LimView profile

Associate Professor

• Nuclear Pore Complex Transport
• Mechanobiology of Cells and Tissues
• Biomimetic Molecular Transport Systems
• +5 more

Prof. Dr. Roderick Lim is an Associate Professor at the Biozentrum, University of Basel , where he leads a research group since 2014. His work bridges biophysics, nanotechnology, and molecular biology , focusing on the nuclear pore complex (NPC) and mechanobiology of cells . He develops biomimetic systems for selective molecular transport and ARTIDIS , a nanomechanical tissue diagnostic platform commercialized for breast cancer prognosis . Education : BSc (UNC Chapel Hill), PhD (NUS/IMRE Singapore), Postdoc (Swiss Nanoscience Institute) Positions : Argovia Professor (2014–present), Tenure Track Asst. Prof. (2009–2013), Postdoc (2004–2008) His research on NPC transport selectivity reveals how karyopherins modulate the FG Nup barrier via multivalent interactions, with implications for viral entry and Alzheimer’s disease . His ARTIDIS platform uses atomic force microscopy to detect cancer via tissue softness, linking hypoxia to metastasis . Recent 2025 publications explore bacterial nanoharpoon defense mechanisms and DNA origami-based NPC mimics . Scientific Awards : Pierre-Gilles de Gennes Prize (2008), A*STAR Fellowship (2004) Collaborations : NCCR Molecular Systems Engineering, NanoTera, KTI He mentors PhD students in institutions across Switzerland, Singapore, Sweden, and the UK , with alumni working on polymersome delivery, mechanotransduction, and pathogen transport . His lab pioneered high-speed atomic force microscopy for real-time NPC dynamics and plasmonic nanopores for synthetic biology applications.

Doron BetelView profile

Assistant Professor

• Computational Genomics
• Bioinformatics
• Single-cell RNA-seq Analysis
• +3 more

Doron Betel serves as an Assistant Professor at Weill Cornell Medicine's Graduate School of Medical Sciences, with affiliations in both the Physiology, Biophysics & Systems Biology and Computational Biology programs. He directs the Applied Bioinformatics Core (ABC), a central service group providing specialized computational and analytical support for biomedical research across multiple institutions. Dr. Betel's research focuses on developing computational genomic tools for studying human diseases and cellular development, with emphasis on integrative analyses of genomic and epigenomic data from high-throughput assays. His work addresses specific questions related to disease progression, treatment response, stem cell differentiation, and neurological processes through two closely interacting research groups: the Applied Bioinformatics Core and his independent research lab. The analysis of his recent publications reveals a strong emphasis on single-cell and spatial genomics, cross-species data integration, and machine learning applications in cancer immunology and neurodegenerative disease modeling. His research spans multiple high-impact areas including cancer immunotherapy, stem cell biology, diabetes research, and cardiovascular regeneration, with numerous publications in top journals like Nature, Cell, and Nature Immunology. Through the Applied Bioinformatics Core, Dr. Betel provides extensive analytical support across various genomic platforms including single-cell RNA-seq, spatial transcriptomics, ChIP-seq, ATAC-seq, and variant calling. The Core serves as a vital resource for researchers at Weill Cornell Medicine and the broader Tri-Institutional network, offering specialized analysis, computational pipelines, and training services. Dr. Betel maintains extensive collaborations with leading researchers including Lorenz Studer at MSKCC for stem cell and neurodegenerative disease research, Tuomas Tammela for cancer genomics, and multiple immunology researchers studying T cell function in autoimmunity and cancer. His work bridges computational methodology development with direct biomedical applications across multiple disease areas.

Felix SchweizerView profile

Professor

• Neurobiology
• Synaptic transmission
• Neurotransmitter release
• +5 more

Felix Schweizer is Professor of Neurobiology at the David Geffen School of Medicine, University of California, Los Angeles, and concurrently serves as Interim Director of the Brain Research Institute and Chair of the Graduate Interdepartmental Program for Neuroscience, reflecting his leadership in both research and graduate training. Education Ph.D. in Biochemistry (summa cum laude), University of Basel, 1989 Research Interests Schweizer’s laboratory focuses on the molecular mechanisms of synaptic transmission and neuronal communication. Using electrophysiology, optical imaging, and quantitative proteomics, his group investigates how protein ubiquitination dynamically regulates neurotransmitter release and neuronal excitability. Recent projects explore microbial metabolite sensing by vagal afferents, the synaptic impact of environmental toxicants linked to Parkinson’s disease, and how gravitational load alters vestibular synaptic architecture. Collaborations with Drs. James Wohlschlegel (multiplexed SILAC proteomics), David Krantz (pesticide neurotoxicology), and Larry Hoffman (vestibular biology in altered gravity) extend the lab’s reach from molecular mechanisms to systems-level neuroscience. Scientific Awards No specific awards are listed in the provided text. Advising & Grants As Chair of the Graduate Interdepartmental Program for Neuroscience, Schweizer oversees interdisciplinary Ph.D. training across UCLA. The laboratory continuously hosts post-doctoral fellows and graduate students, and recent funding supports work on ubiquitin-mediated synaptic modulation, pesticide-induced neurodegeneration, and spaceflight-induced synaptic plasticity in the vestibular system. Labs & Teams The Schweizer laboratory, located in the Center for Health Sciences at UCLA, integrates electrophysiology, advanced imaging (serial EM and EM tomography), and biochemical approaches to dissect synaptic function across rodent, Drosophila, and human tissue models.

Bjoern BauerView profile

Professor

• Neuroscience
• Alzheimer’s Disease
• Blood-Brain Barrier Physiology
• +3 more

Bjoern Bauer, PhD is a Professor in the Department of Pharmaceutical Sciences at the University of Kentucky, affiliated with the Sanders-Brown Center on Aging. His research focuses on blood-brain barrier (BBB) biology, Alzheimer’s disease mechanisms, and drug delivery strategies for neurological disorders. Bauer’s work explores how BBB dysfunction contributes to neurodegenerative diseases and cancer, with particular attention to efflux transporters like P-glycoprotein (ABCB1) and their roles in drug resistance and amyloid beta pathology. Key research areas include: 1) BBB leakage and its role in Alzheimer’s disease progression, 2) development of therapeutic strategies to modulate BBB transporters, 3) preclinical models of glioblastoma and neurodegeneration, and 4) biomarker discovery for early disease detection. His lab utilizes advanced in vitro BBB models, transgenic mouse models (e.g., 5xFAD), and imaging techniques to study these processes. Bauer’s contributions span over 40 peer-reviewed publications since 2001, with recent work emphasizing oxidative stress mechanisms, tumor drug resistance, and translational approaches to BBB targeting. Current efforts include investigating S100β as a plasma biomarker and exploring proteasome inhibition as a therapeutic avenue for restoring BBB integrity. He leads the Bauer-Hartz Lab, collaborating extensively with neurologists, oncologists, and pharmacologists to advance CNS drug delivery technologies. He holds a PhD in Pharmacology and has been a faculty member at the University of Kentucky since joining Sanders-Brown in [year not explicitly stated]. His research is supported by grants focusing on BBB biology, Alzheimer’s disease, and cancer pharmacology.

Jochen HermsView profile

Professor

• Biomedical Neuroscience
• Cellular & Systems Neuroscience
• Behavioral & Cognitive Neuroscience
• +5 more

Prof. Dr. Jochen Herms serves as Director at the LMU Center for Neuropathology and Prion Research , while maintaining a dual affiliation with the German Center for Neurodegenerative Diseases (DZNE) Munich as Head of Translational Brain Research. His work bridges clinical and experimental neuropathology, focusing on synaptic degeneration in neurodegenerative conditions. Ludwig-Maximilians-Universität München (LMU): Director, Experimental Neuropathology DZNE Munich: Translational Brain Research Research Themes: Primary: Biomedical Neuroscience Secondary: Cellular & Systems Neuroscience Tertiary: Behavioral & Cognitive Neuroscience Key investigations include: Physiological roles of neurodegenerative disease proteins (APP, presenilins, BACE, tau, α-synuclein) In vivo two-photon imaging of transgenic Alzheimer's models Neuronal calcium homeostasis in neurodegeneration High-throughput drug screening for AD/PD Active research collaborations leverage funding from: German Research Foundation (DFG) - Munich Cluster for Systems Neurology (EXC 2145 SyNergy) BMBF, BMWi, EU consortia Bavarian Research Foundation Wilhelm Sander Foundation